Abstract:Background: Pathological cardiac fibrosis and hypertrophy, the common features of left ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 (Foxp1) in endothelial cells (ECs) has been shown to play an important role in heart development. However, the effect of EC-Foxp1 on pathological cardiac remodeling has not been well clarified. This study aims to determine the role of EC-Foxp1 in pathological cardiac remodeling and the underlying mechanisms. Methods: Foxp1 EC-specific loss-of-function and gain-of-function mice were generated, and an angiotensin II infusion or a transverse aortic constriction operation mouse model was used to study the cardiac remodeling mechanisms. Foxp1 downstream target gene transforming growth factor-beta 1 (TGF-beta 1) was confirmed by chromatin immunoprecipitation and luciferase assays. Finally, the effects of TGF-beta 1 blockade on EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes were further confirmed by pharmacological inhibition, more specifically by RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Results: Foxp1 expression is significantly downregulated in cardiac ECs during angiotensin II-induced cardiac remodeling. EC-Foxp1 deletion results in severe cardiac remodeling, including more cardiac fibrosis with myofibroblast formation and extracellular matrix protein production, as well as decompensated cardiac hypertrophy and further exacerbation of cardiac dysfunction on angiotensin II infusion or transverse aortic constriction operation. In contrast, EC-Foxp1 gain of function protects against pathological cardiac remodeling and improves cardiac dysfunction. TGF-beta 1 signals are identified as Foxp1 direct target genes, and EC-Foxp1 deletion upregulates TGF-beta 1 signals to promote myofibroblast formation through fibroblast proliferation and transformation, resulting in severe cardiac fibrosis. Moreover, EC-Foxp1 deletion enhances TGF-beta 1-promoted endothelin-1 expression, which significantly increases cardiomyocyte size and reactivates cardiac fetal genes, leading to pathological cardiac hypertrophy. Correspondingly, these EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes and cardiac dysfunction are normalized by the blockade of TGF-beta 1 signals through pharmacological inhibition and RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Conclusions: EC-Foxp1 regulates the TGF-beta 1-endothelin-1 pathway to control pathological cardiac fibrosis and hypertrophy, resulting in cardiac dysfunction. Therefore, targeting the EC-Foxp1-TGF-beta 1-endothelin-1 pathway might provide a future novel therapy for heart failure.

GTF2H4 Regulates Partial EndMT Via NF-κB Activation Through NCOA3 Phosphorylation in Ischemic Diseases

Acetate Controls Endothelial-to-mesenchymal Transition

TNFR 2 Stimulation Promotes Mitochondrial Fusion Via Stat 3-and NF-kB – Dependent Activation of OPA 1 Expression

The Protective Role of Bfgf in Myocardial Infarction and Hypoxia Cardiomyocytes by Reducing Oxidative Stress Via Nrf2

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1-driven fibrotic remodeling in ischemic heart failure

ZNF354C Mediated by DNMT1 Ameliorates Lung Ischemia-Reperfusion Oxidative Stress Injury by Reducing TFPI Promoter Methylation to Upregulate TFPI

Inhibition of BRD4 Attenuates Transverse Aortic Constriction- and TGF-β-induced Endothelial-Mesenchymal Transition and Cardiac Fibrosis.

Crosstalk between endothelial cells with a non-canonical EndoMT phenotype and cardiomyocytes/fibroblasts via IGFBP5 aggravates TAC-induced cardiac dysfunction

TGF--mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

GATA4 regulates mitochondrial biogenesis and functions during cardiac development and rescues cardiac and mitochondrial functions impaired by TKIs

TGF-&#946;-mediated Endothelial to Mesenchymal Transition (endmt) and the Functional Assessment of EndMT Effectors Using CRISPR/Cas9 Gene Editing

NADPH Oxidase-Dependent Redox Signaling in TGF-β-mediated Fibrotic Responses

TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing.

Endothelial TET2 Regulates Cardiac Remodeling by Modifying Endothelial-to-Mesenchymal Transition

Glycolysis Promotes Angiotensin II–Induced Aortic Remodeling Through Regulating Endothelial-to-Mesenchymal Transition via the Corepressor C-Terminal Binding Protein 1

Neuronal-targeted TFEB rescues dysfunction of the autophagy-lysosomal pathway and alleviates ischemic injury in permanent cerebral ischemia

CHMP4C Deficiency Represses Angiogenesis in Chronic Ischemia by Inhibiting Hypoxia-induced Wnt/β-catenin Signaling Activation Via GSK3β

Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition

TNC Accelerates Hypoxia-Induced Cardiac Injury in a METTL3-Dependent Manner

Abstract 13694: Hsf1 Attenuates Pressure Overload Induced-cardiac Fibrosis via Inhibiting Smad3 Phosphorylation and Nuclear Translocation